Page last updated: 2024-11-06

nsc 361456

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

pyrazine-2-diazohydroxide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72766
CHEMBL ID2008749
SCHEMBL ID671572
MeSH IDM0146322

Synonyms (29)

Synonym
NCI60_003296
brn 0774915
nsc 361456
diazohydroxide
n-nitrosopyrazinamine
pyrazinamine, n-nitroso-
2-pyrazine diazohydroxide
pyrazine-2-diazohydroxide
pyrazine diazohydroxide
nsc361456
nsc-361456
103829-56-7
nsc-374153
(e)-hydroxy(pyrazin-2-yl)diazene
n-nitrosopyrazin-2-amine
n-pyrazin-2-ylnitrous amide
AKOS006273168
unii-m0610gt9kv
m0610gt9kv ,
SCHEMBL671572
CHEMBL2008749
AUWFXUHWMBMPTI-UHFFFAOYSA-N
2-[(e)-hydroxydiazenyl]pyrazine #
2-pyrazinamine, n-nitroso-
pyrazine, 2-diazohydroxide
DTXSID50869407
EN300-7331341
(e)-n-[(pyrazin-2-yl)imino]hydroxylamine
PD159749

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Human BFU-e were greatly inhibited by PZDH, whereas murine BFU-e were relatively resistant to its toxic effects."( Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.
Du, DL; Grieshaber, CK; Murphy, MJ; Volpe, DA, 1991
)
0.28

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma elimination was fit to one (12/16) or two (4/16) compartment model with a mean k10 half-life of 11."( Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
Ames, MM; Dhodapkar, MV; Reid, JM; Richardson, RL, 1994
)
0.29
" Pharmacokinetic evaluations were performed on 28 of the 31 patients using an analytical method including derivatization of the parent drug to 2-chloropyrazine."( Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Berezin, F; Janisch, L; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 1994
)
0.51
" Pharmacodynamic analysis revealed no significant correlation between plasma levels at 5, 60, and 120 min; WBCs; absolute neutrophil and platelet count nadirs; and initial serum chloride or blood pH levels."( Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Ansari, RH; Brockstein, BE; Garcia, JC; Mani, S; Meyer, SC; Mick, R; Ratain, MJ; Rhinehart, SN; Schilsky, RL; Stadler, WM; Taber, D; Vogelzang, NJ; Vokes, EE, 1998
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (28.57)18.7374
1990's8 (57.14)18.2507
2000's1 (7.14)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (42.86%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]